Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Rating of "Buy" by Analysts

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) have been given a consensus recommendation of "Buy" by the five brokerages that are currently covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $41.20.

A number of equities research analysts have commented on ELVN shares. Jones Trading reduced their target price on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a report on Friday, May 16th. HC Wainwright raised their price target on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a research report on Wednesday, July 2nd. Robert W. Baird raised their price objective on Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a research note on Monday, June 16th. Finally, The Goldman Sachs Group started coverage on shares of Enliven Therapeutics in a research note on Monday, June 16th. They set a "buy" rating and a $37.00 price objective on the stock.

Insider Transactions at Enliven Therapeutics

In other Enliven Therapeutics news, COO Anish Patel sold 6,667 shares of the business's stock in a transaction on Monday, July 7th. The stock was sold at an average price of $19.79, for a total value of $131,939.93. Following the transaction, the chief operating officer owned 296,642 shares of the company's stock, valued at approximately $5,870,545.18. The trade was a 2.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Benjamin Hohl sold 3,250 shares of the business's stock in a transaction on Friday, June 27th. The stock was sold at an average price of $20.91, for a total value of $67,957.50. Following the completion of the transaction, the chief financial officer directly owned 23,000 shares in the company, valued at approximately $480,930. This represents a 12.38% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 100,111 shares of company stock valued at $1,951,216. Company insiders own 25.90% of the company's stock.

Hedge Funds Weigh In On Enliven Therapeutics

Several large investors have recently made changes to their positions in ELVN. Charles Schwab Investment Management Inc. lifted its stake in shares of Enliven Therapeutics by 2.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 261,888 shares of the company's stock valued at $5,892,000 after acquiring an additional 6,611 shares during the period. Swiss National Bank increased its holdings in shares of Enliven Therapeutics by 13.9% in the fourth quarter. Swiss National Bank now owns 41,873 shares of the company's stock worth $942,000 after acquiring an additional 5,100 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of Enliven Therapeutics during the fourth quarter worth about $367,000. KLP Kapitalforvaltning AS bought a new position in shares of Enliven Therapeutics during the fourth quarter worth about $97,000. Finally, Vanguard Group Inc. boosted its position in Enliven Therapeutics by 2.9% during the fourth quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company's stock valued at $44,452,000 after purchasing an additional 55,283 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company's stock.

Enliven Therapeutics Stock Up 2.4%

NASDAQ ELVN traded up $0.55 during trading on Friday, hitting $23.00. The stock had a trading volume of 416,248 shares, compared to its average volume of 365,253. Enliven Therapeutics has a twelve month low of $13.30 and a twelve month high of $30.03. The company has a market capitalization of $1.13 billion, a PE ratio of -11.98 and a beta of 0.83. The firm has a 50 day moving average price of $19.77 and a 200 day moving average price of $20.26.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). On average, sell-side analysts anticipate that Enliven Therapeutics will post -1.95 earnings per share for the current year.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.